Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
Identifieur interne : 002C63 ( PubMed/Checkpoint ); précédent : 002C62; suivant : 002C64Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
Auteurs : Hong Zhang [République populaire de Chine] ; Guangwen Wang ; Jian Li ; Yuchun Nie ; Xuanling Shi ; Gewei Lian ; Wei Wang ; Xiaolei Yin ; Yang Zhao ; Xiuxia Qu ; Mingxiao Ding ; Hongkui DengSource :
- Journal of virology [ 0022-538X ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Données de séquences moléculaires, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (), Glycoprotéines membranaires (immunologie), Humains, Immunisation, Lapins, Protéines de l'enveloppe virale (), Protéines de l'enveloppe virale (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Séquence d'acides aminés, Tests de neutralisation, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie), Épitopes.
- MESH :
- administration et posologie : Vaccins antiviraux.
- immunologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- sang : Anticorps antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Données de séquences moléculaires, Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Humains, Immunisation, Lapins, Protéines de l'enveloppe virale, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Séquence d'acides aminés, Tests de neutralisation, Épitopes.
English descriptors
- KwdEn :
- Amino Acid Sequence, Animals, Antibodies, Viral (blood), Epitopes, Female, Humans, Immunization, Membrane Glycoproteins (chemistry), Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Rabbits, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , chemistry : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Amino Acid Sequence, Animals, Epitopes, Female, Humans, Immunization, Mice, Mice, Inbred BALB C, Molecular Sequence Data, Neutralization Tests, Rabbits, Spike Glycoprotein, Coronavirus.
Abstract
Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a newly identified coronavirus (CoV), SARS-CoV. The spike (S) glycoprotein of CoV is the major structural protein responsible for induction of host immune response and virus neutralization by antibodies. Hence, knowledge of neutralization determinants on the S protein is helpful for designing protective vaccines. To analyze the antigenic structure of the SARS-CoV S2 domain, the carboxyl-terminal half of the S protein, we first used sera from convalescent SARS patients to test the antigenicity of 12 overlapping fragments spanning the entire S2 and identified two antigenic determinants (Leu 803 to Ala 828 and Pro 1061 to Ser 1093). To determine whether neutralizing antibodies can be elicited by these two determinants, we immunized animals and found that both of them could induce the S2-specific antisera. In some animals, however, only one determinant (Leu 803 to Ala 828) was able to induce the antisera with the binding ability to the native S protein and the neutralizing activity to the SARS-CoV pseudovirus. This determinant is highly conserved across different SARS-CoV isolates. Identification of a conserved antigenic determinant on the S2 domain of the SARS-CoV S protein, which has the potential for inducing neutralizing antibodies, has implications in the development of effective vaccines against SARS-CoV.
DOI: 10.1128/JVI.78.13.6938-6945.2004
PubMed: 15194770
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15194770Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.</title>
<author><name sortKey="Zhang, Hong" sort="Zhang, Hong" uniqKey="Zhang H" first="Hong" last="Zhang">Hong Zhang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
<orgName type="university">Université de Pékin</orgName>
<placeName><settlement type="city">Pékin</settlement>
<region type="capitale">Pékin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Guangwen" sort="Wang, Guangwen" uniqKey="Wang G" first="Guangwen" last="Wang">Guangwen Wang</name>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
</author>
<author><name sortKey="Nie, Yuchun" sort="Nie, Yuchun" uniqKey="Nie Y" first="Yuchun" last="Nie">Yuchun Nie</name>
</author>
<author><name sortKey="Shi, Xuanling" sort="Shi, Xuanling" uniqKey="Shi X" first="Xuanling" last="Shi">Xuanling Shi</name>
</author>
<author><name sortKey="Lian, Gewei" sort="Lian, Gewei" uniqKey="Lian G" first="Gewei" last="Lian">Gewei Lian</name>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Yin, Xiaolei" sort="Yin, Xiaolei" uniqKey="Yin X" first="Xiaolei" last="Yin">Xiaolei Yin</name>
</author>
<author><name sortKey="Zhao, Yang" sort="Zhao, Yang" uniqKey="Zhao Y" first="Yang" last="Zhao">Yang Zhao</name>
</author>
<author><name sortKey="Qu, Xiuxia" sort="Qu, Xiuxia" uniqKey="Qu X" first="Xiuxia" last="Qu">Xiuxia Qu</name>
</author>
<author><name sortKey="Ding, Mingxiao" sort="Ding, Mingxiao" uniqKey="Ding M" first="Mingxiao" last="Ding">Mingxiao Ding</name>
</author>
<author><name sortKey="Deng, Hongkui" sort="Deng, Hongkui" uniqKey="Deng H" first="Hongkui" last="Deng">Hongkui Deng</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15194770</idno>
<idno type="pmid">15194770</idno>
<idno type="doi">10.1128/JVI.78.13.6938-6945.2004</idno>
<idno type="wicri:Area/PubMed/Corpus">002D37</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D37</idno>
<idno type="wicri:Area/PubMed/Curation">002D37</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D37</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C63</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C63</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.</title>
<author><name sortKey="Zhang, Hong" sort="Zhang, Hong" uniqKey="Zhang H" first="Hong" last="Zhang">Hong Zhang</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
<orgName type="university">Université de Pékin</orgName>
<placeName><settlement type="city">Pékin</settlement>
<region type="capitale">Pékin</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wang, Guangwen" sort="Wang, Guangwen" uniqKey="Wang G" first="Guangwen" last="Wang">Guangwen Wang</name>
</author>
<author><name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
</author>
<author><name sortKey="Nie, Yuchun" sort="Nie, Yuchun" uniqKey="Nie Y" first="Yuchun" last="Nie">Yuchun Nie</name>
</author>
<author><name sortKey="Shi, Xuanling" sort="Shi, Xuanling" uniqKey="Shi X" first="Xuanling" last="Shi">Xuanling Shi</name>
</author>
<author><name sortKey="Lian, Gewei" sort="Lian, Gewei" uniqKey="Lian G" first="Gewei" last="Lian">Gewei Lian</name>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Yin, Xiaolei" sort="Yin, Xiaolei" uniqKey="Yin X" first="Xiaolei" last="Yin">Xiaolei Yin</name>
</author>
<author><name sortKey="Zhao, Yang" sort="Zhao, Yang" uniqKey="Zhao Y" first="Yang" last="Zhao">Yang Zhao</name>
</author>
<author><name sortKey="Qu, Xiuxia" sort="Qu, Xiuxia" uniqKey="Qu X" first="Xiuxia" last="Qu">Xiuxia Qu</name>
</author>
<author><name sortKey="Ding, Mingxiao" sort="Ding, Mingxiao" uniqKey="Ding M" first="Mingxiao" last="Ding">Mingxiao Ding</name>
</author>
<author><name sortKey="Deng, Hongkui" sort="Deng, Hongkui" uniqKey="Deng H" first="Hongkui" last="Deng">Hongkui Deng</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Epitopes</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization</term>
<term>Membrane Glycoproteins (chemistry)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>Rabbits</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Viral Envelope Proteins (chemistry)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Données de séquences moléculaires</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires ()</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Lapins</term>
<term>Protéines de l'enveloppe virale ()</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Séquence d'acides aminés</term>
<term>Tests de neutralisation</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de l'enveloppe virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Epitopes</term>
<term>Female</term>
<term>Humans</term>
<term>Immunization</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Molecular Sequence Data</term>
<term>Neutralization Tests</term>
<term>Rabbits</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Données de séquences moléculaires</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires</term>
<term>Humains</term>
<term>Immunisation</term>
<term>Lapins</term>
<term>Protéines de l'enveloppe virale</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Séquence d'acides aminés</term>
<term>Tests de neutralisation</term>
<term>Épitopes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a newly identified coronavirus (CoV), SARS-CoV. The spike (S) glycoprotein of CoV is the major structural protein responsible for induction of host immune response and virus neutralization by antibodies. Hence, knowledge of neutralization determinants on the S protein is helpful for designing protective vaccines. To analyze the antigenic structure of the SARS-CoV S2 domain, the carboxyl-terminal half of the S protein, we first used sera from convalescent SARS patients to test the antigenicity of 12 overlapping fragments spanning the entire S2 and identified two antigenic determinants (Leu 803 to Ala 828 and Pro 1061 to Ser 1093). To determine whether neutralizing antibodies can be elicited by these two determinants, we immunized animals and found that both of them could induce the S2-specific antisera. In some animals, however, only one determinant (Leu 803 to Ala 828) was able to induce the antisera with the binding ability to the native S protein and the neutralizing activity to the SARS-CoV pseudovirus. This determinant is highly conserved across different SARS-CoV isolates. Identification of a conserved antigenic determinant on the S2 domain of the SARS-CoV S protein, which has the potential for inducing neutralizing antibodies, has implications in the development of effective vaccines against SARS-CoV.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15194770</PMID>
<DateCompleted><Year>2004</Year>
<Month>07</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>78</Volume>
<Issue>13</Issue>
<PubDate><Year>2004</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.</ArticleTitle>
<Pagination><MedlinePgn>6938-45</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a life-threatening disease caused by a newly identified coronavirus (CoV), SARS-CoV. The spike (S) glycoprotein of CoV is the major structural protein responsible for induction of host immune response and virus neutralization by antibodies. Hence, knowledge of neutralization determinants on the S protein is helpful for designing protective vaccines. To analyze the antigenic structure of the SARS-CoV S2 domain, the carboxyl-terminal half of the S protein, we first used sera from convalescent SARS patients to test the antigenicity of 12 overlapping fragments spanning the entire S2 and identified two antigenic determinants (Leu 803 to Ala 828 and Pro 1061 to Ser 1093). To determine whether neutralizing antibodies can be elicited by these two determinants, we immunized animals and found that both of them could induce the S2-specific antisera. In some animals, however, only one determinant (Leu 803 to Ala 828) was able to induce the antisera with the binding ability to the native S protein and the neutralizing activity to the SARS-CoV pseudovirus. This determinant is highly conserved across different SARS-CoV isolates. Identification of a conserved antigenic determinant on the S2 domain of the SARS-CoV S protein, which has the potential for inducing neutralizing antibodies, has implications in the development of effective vaccines against SARS-CoV.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Hong</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Cell Biology and Genetics, College of Life Sciences, Peking University, Beijing 100871, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Guangwen</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Jian</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Nie</LastName>
<ForeName>Yuchun</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Shi</LastName>
<ForeName>Xuanling</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lian</LastName>
<ForeName>Gewei</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yin</LastName>
<ForeName>Xiaolei</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhao</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Qu</LastName>
<ForeName>Xiuxia</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ding</LastName>
<ForeName>Mingxiao</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Deng</LastName>
<ForeName>Hongkui</ForeName>
<Initials>H</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000939">Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000939" MajorTopicYN="Y">Epitopes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15194770</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.78.13.6938-6945.2004</ArticleId>
<ArticleId IdType="pii">78/13/6938</ArticleId>
<ArticleId IdType="pmc">PMC421668</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Biol. 2003 Jul 25;330(5):1101-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12860131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 Sep 26;301(5641):1824</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14512588</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Jan 2;303(5654):26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14704402</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Mar 5;315(2):439-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14766227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1982 Jun;119(2):358-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6281979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1983 Apr;64 (Pt 4):761-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6300299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1984 Jan 30;132(2):250-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6199888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 1985 Jun;2(4):317-28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2412363</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1985 Dec;56(3):904-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2999443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1985 Dec;56(3):912-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2999444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1987 Dec;161(2):479-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2825419</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1988 Dec;69 ( Pt 12):2939-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3058868</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1989 Mar;63(3):1408-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2464703</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Immunol. 1989 Jan;26(1):7-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2467199</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1990 Feb;71 ( Pt 2):487-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2155300</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1990 May;176(1):296-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2184576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1993 Mar;67(3):1185-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7679743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1994 Aug 1;202(2):540-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8030220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1994 Sep;68(9):5403-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7520090</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1995 Nov;69(11):7260-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7474149</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1996 Jun 20;381(6584):661-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8649511</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 1997;142(11):2249-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9672590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7774-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10393897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2000 May 25;271(1):182-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10814583</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2001 Jan 20;279(2):371-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11162792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 2001;494:609-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11774533</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2002 Sep 15;301(1):109-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12359451</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Jan;77(1):353-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12477840</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1990 Jul;64(7):3304-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1693702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1990 Dec;64(12):6270-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1700835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 1991 Mar;18(2-3):99-107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1645909</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1992 Jul;73 ( Pt 7):1725-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1378480</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1992 Dec;73 ( Pt 12):3289-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1281870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Oct 1;21(27-30):4095-104</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14505885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2003 Oct 10;310(1):78-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14511651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Feb;77(4):2607-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12551999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12644702</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<region><li>Pékin</li>
</region>
<settlement><li>Pékin</li>
</settlement>
<orgName><li>Université de Pékin</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Deng, Hongkui" sort="Deng, Hongkui" uniqKey="Deng H" first="Hongkui" last="Deng">Hongkui Deng</name>
<name sortKey="Ding, Mingxiao" sort="Ding, Mingxiao" uniqKey="Ding M" first="Mingxiao" last="Ding">Mingxiao Ding</name>
<name sortKey="Li, Jian" sort="Li, Jian" uniqKey="Li J" first="Jian" last="Li">Jian Li</name>
<name sortKey="Lian, Gewei" sort="Lian, Gewei" uniqKey="Lian G" first="Gewei" last="Lian">Gewei Lian</name>
<name sortKey="Nie, Yuchun" sort="Nie, Yuchun" uniqKey="Nie Y" first="Yuchun" last="Nie">Yuchun Nie</name>
<name sortKey="Qu, Xiuxia" sort="Qu, Xiuxia" uniqKey="Qu X" first="Xiuxia" last="Qu">Xiuxia Qu</name>
<name sortKey="Shi, Xuanling" sort="Shi, Xuanling" uniqKey="Shi X" first="Xuanling" last="Shi">Xuanling Shi</name>
<name sortKey="Wang, Guangwen" sort="Wang, Guangwen" uniqKey="Wang G" first="Guangwen" last="Wang">Guangwen Wang</name>
<name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
<name sortKey="Yin, Xiaolei" sort="Yin, Xiaolei" uniqKey="Yin X" first="Xiaolei" last="Yin">Xiaolei Yin</name>
<name sortKey="Zhao, Yang" sort="Zhao, Yang" uniqKey="Zhao Y" first="Yang" last="Zhao">Yang Zhao</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Zhang, Hong" sort="Zhang, Hong" uniqKey="Zhang H" first="Hong" last="Zhang">Hong Zhang</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002C63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:15194770 |texte= Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15194770" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |